Patents by Inventor Isabelle Cremer

Isabelle Cremer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PROGNOSIS AND TREATING A PATIENT SUFFERING FROM CANCER
    Publication number: 20240132974
    Abstract: Complement components form a plasma innate immune cascade but could also serve as multitasking proteins, as they have functions beyond this system. Here, we show that complement FH is locally expressed by multiple types of human tumors. We provide a paradigm shift for the impact of FH on cancer progression, showing a previously unrecognized, intracellular function of FH outside the complement cascade, while the canonical, complement-regulatory function had no effect. Int-FH served as a driver of the proliferation and migration of ccRCC and lung ADK cells but not of normal cells or lung SCC cells. The presence of int-FH staining in tumor cells indicated poor prognosis for ccRCC and lung ADK.
    Type: Application
    Filed: February 11, 2022
    Publication date: April 25, 2024
    Inventors: Lubka ROUMENINA, Marie DAUGAN, Margot REVEL, Isabelle CREMER, Catherine SAUTES-FRIDMAN, Wolf Herman FRIDMAN
  • METHODS FOR PREDICTING THE RESPONSE TO ANTI-CANCER TREATMENT WITH AN AGONIST OF TLR7 OR AN AGONIST OF TLR8
    Publication number: 20140288018
    Abstract: The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient.
    Type: Application
    Filed: March 27, 2014
    Publication date: September 25, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale )
    Inventors: Julien Cherfils, Herve Fridman, Isabelle Cremer
  • Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8
    Patent number: 8772243
    Abstract: The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: July 8, 2014
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Julien Cherfils, Herve Fridman, Isabelle Cremer
  • Methods for Predicting the Response to Anti-Cancer Treatment with an Agonist of TLR7 or an Agonist of TLR8
    Publication number: 20110195923
    Abstract: The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient.
    Type: Application
    Filed: August 14, 2009
    Publication date: August 11, 2011
    Applicant: INSERM (institiut National de la Sante et de la Re cherche medicale)
    Inventors: Julien Cherfils, Herve Fridman, Isabelle Cremer